Topics
Glioblastoma | Treatment | Clinical trials | Navtemadlin
Home > Publications > Topics > Glioblastoma > Treatment > Clinical trials > Navtemadlin
Rendo V, Lee EQ, Bossi C, Khuu N, Rudek MA, Pal S, Reynolds ARN,
Fassinou ACR, Ayoub G, Lapinskas E, Pisano W, Jeang J, Stopka SA,
Regan MS, Spetz J, Desai A, Lieberman F, Fisher JD, Pelton K,
Huang RY, Nabors LB, Holdhoff M, Danda N, Strowd R, Desideri S,
Walbert T, Ye X, Agar NYR, Grossman SA, Alexander BM, Wen PY,
Ligon KL, Beroukhim R.
Surgical window
of opportunity trial reveals
mechanisms of response and resistance
to navtemadlin (KRT-232) in patients with
recurrent glioblastoma.
medRxiv
[Preprint]. 2024 Aug 14:2024.08.12.24311893. doi:
10.1101/2024.08.12.24311893. PMID:
39211865. Interventional study. ˍ